Skip to content

Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh

A Prospective Study Evaluating the Clinical Outcomes of Ventral or Inguinal Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04779918
Acronym
BRAVOII
Enrollment
160
Registered
2021-03-03
Start date
2021-04-29
Completion date
2029-12-30
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hernia, Inguinal, Hernia, Ventral

Keywords

use of mesh, robotic hernia repair

Brief summary

This study is designed to evaluate the post-operative complications and hernia recurrence following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.

Detailed description

This study is intended to evaluate the post-operative complications and recurrence following the use of OviTex in ventral or inguinal hernias being treated robotically. It is a single-arm study and all subjects will receive OviTex.

Interventions

All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.

Sponsors

Tela Bio Inc
Lead SponsorINDUSTRY
MCRA
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subject suffers from a ventral or inguinal hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue. 2. The patient is scheduled for an elective robotic approach with the use of OviTex LPR, OviTex Core Permanent, OviTex 1S Permanent, or OviTex IHR. 3. The size of the implant needed for repair is expected to be less than or equal to 15 x 25 cm for OviTex LPR and 25 x 40 cm for OviTex Core Permanent and OviTex 1S Permanent, with no size limitation for OviTex IHR. 4. Subject meets CDC/SSI Wound Classification Class I (Clean), Class II (Clean-Contaminated) or Class III (Contaminated) criteria. 5. Subject is willing and able to sign an informed consent for the study and has signed the IRB approved Informed Consent form for this study. 6. Subject is able to complete Quality of Life (QoL) and pain questionnaires. 7. Subject is at least 21 years old. 8. Subject is willing to comply and able to participate fully in, and for the full duration of, the study including follow-up requirements.

Exclusion criteria

at Baseline: 1. Subject has a BMI of \> 40 2. Subject meets CDC/SSI Wound Classification Class IV (Dirty-Infected) criteria 3. Subject is female and is pregnant or plans to become pregnant during the course of the study. 4. Subject has a life expectancy of \< 2 years making it unlikely that the subject will successfully achieve two-year follow-up. 5. Subject has recent history of drug or alcohol abuse (in last 3 years). 6. Subject has an allergy to ovine-derived products. 7. Subject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial. 8. Subject has a strangulated hernia.

Design outcomes

Primary

MeasureTime frameDescription
Early surgical site occurrences or wound related eventsoccurring within the first 3 months of the ventral or inguinal hernia repairIncidence of early peri- and post-operative surgical site occurrences or wound related events noted at the hernia repair site
Early post-operative complicationsoccurring within the first 3 months of the ventral or inguinal hernia repair.Incidence of other early post-operative complications

Secondary

MeasureTime frameDescription
Late surgical site occurrences or wound related eventsoccurring > 3 months after index surgeryIncidence of late post-operative surgical site occurrences or wound related events noted at the hernia repair site
Late post-operative complicationsoccurring > 3 months after index surgery.Incidence of other late post-operative complications
Patient Reported OutcomesAssessed at day 30, day 90, 12 months, and 24 months post-opPatient Reported Outcomes (QoL and pain assessments)
Hernia Recurrenceat post-operative day 90 and months 12 and 24True hernia recurrence at the site of surgery

Countries

United States

Contacts

CONTACTMelissa LaMantia
mlamantia@telabio.com757-761-4922
CONTACTDanielle Campbell
dcampbell@telabio.com717-676-2589
PRINCIPAL_INVESTIGATORGeoffrey Slayden, MD

St. Lukes Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026